Dermapharm Forecast, price target & analysts
Dermapharm Target price 2025 - Analyst rating & recommendation
Dermapharm Classifications & Recommendation:
Dermapharm Price Target
| Target Price | €44.40 |
| Price | €35.20 |
| Potential |
26.14%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Dermapharm 2026 .
The average Dermapharm target price is €44.40.
This is
26.14%
register free of charge
€49.00
39.20%
register free of charge
€36.00
2.27%
register free of charge
|
|
| A rating was issued by 5 analysts: 5 Analysts recommend Dermapharm to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Dermapharm stock has an average upside potential 2026 of
26.14%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 1.18 | 1.20 |
| 4.00% | 1.28% | |
| EBITDA Margin | 25.23% | 27.42% |
| 6.07% | 8.69% | |
| Net Margin | 9.62% | 10.68% |
| 74.90% | 11.01% |
5 Analysts have issued a sales forecast Dermapharm 2025 . The average Dermapharm sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Dermapharm EBITDA forecast 2025. The average Dermapharm EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Dermapharm Analysts have issued a net profit forecast 2025. The average Dermapharm net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 2.11 | 2.37 |
| 81.90% | 12.32% | |
| P/E | 14.84 | |
| EV/Sales | 2.31 |
4 Analysts have issued a Dermapharm forecast for earnings per share. The average Dermapharm EPS is
This results in the following potential growth metrics and future valuations:
Current Dermapharm Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| MWB RESEARCH AG |
Locked
➜
Locked
|
Locked | Mar 30 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Dec 08 2024 |
| MWB RESEARCH AG |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
MWB RESEARCH AG:
Locked
➜
Locked
|
Mar 30 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Dec 08 2024 |
|
Locked
MWB RESEARCH AG:
Locked
➜
Locked
|
Nov 14 2024 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
